Attached files
Exhibit 24
POWER OF ATTORNEY
The undersigned hereby authorizes and appoints Donald E. Morel, Jr. and John R. Gailey III, and each of them, as his attorneys-in-fact to sign on his behalf and in his capacity as a director of West Pharmaceutical Services, Inc., and to file, the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2011 and all amendments, exhibits and supplements thereto.
Date: February 21, 2012 /s/ Mark A. Buthman
Mark A. Buthman
POWER OF ATTORNEY
The undersigned hereby authorizes and appoints Donald E. Morel, Jr. and John R. Gailey III, and each of them, as his attorneys-in-fact to sign on his behalf and in his capacity as a director of West Pharmaceutical Services, Inc., and to file, the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2011 and all amendments, exhibits and supplements thereto.
Date: February 21, 2012 /s/ Thomas W. Hofmann
Thomas W. Hofmann
POWER OF ATTORNEY
The undersigned hereby authorizes and appoints Donald E. Morel, Jr. and John R. Gailey III, and each of them, as his attorneys-in-fact to sign on his behalf and in his capacity as a director of West Pharmaceutical Services, Inc., and to file, the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2011 and all amendments, exhibits and supplements thereto.
Date: February 21, 2012 /s/ L. Robert Johnson
L. Robert Johnson
POWER OF ATTORNEY
The undersigned hereby authorizes and appoints Donald E. Morel, Jr. and John R. Gailey III, and each of them, as her attorneys-in-fact to sign on her behalf and in her capacity as a director of West Pharmaceutical Services, Inc., and to file, the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2011 and all amendments, exhibits and supplements thereto.
Date: February 21, 2012 /s/ Paula A. Johnson
Paula A. Johnson
POWER OF ATTORNEY
The undersigned hereby authorizes and appoints Donald E. Morel, Jr. and John R. Gailey III, and each of them, as his attorneys-in-fact to sign on his behalf and in his capacity as a director of West Pharmaceutical Services, Inc., and to file, the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2011 and all amendments, exhibits and supplements thereto.
Date: February 21, 2012 /s/ Douglas A. Michels
Douglas A. Michels
POWER OF ATTORNEY
The undersigned hereby authorizes and appoints Donald E. Morel, Jr. and John R. Gailey III, and each of them, as his attorneys-in-fact to sign on his behalf and in his capacity as a director of West Pharmaceutical Services, Inc., and to file, the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2011 and all amendments, exhibits and supplements thereto.
Date: February 21, 2012 /s/ John H. Weiland
John H. Weiland
POWER OF ATTORNEY
The undersigned hereby authorizes and appoints Donald E. Morel, Jr. and John R. Gailey III, and each of them, as his attorneys-in-fact to sign on his behalf and in his capacity as a director of West Pharmaceutical Services, Inc., and to file, the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2011 and all amendments, exhibits and supplements thereto.
Date: February 21, 2012 /s/ Anthony Welters
Anthony Welters
POWER OF ATTORNEY
The undersigned hereby authorizes and appoints Donald E. Morel, Jr. and John R. Gailey III, and each of them, as his attorneys-in-fact to sign on his behalf and in his capacity as a director of West Pharmaceutical Services, Inc., and to file, the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2011 and all amendments, exhibits and supplements thereto.
Date: February 21, 2012 /s/ Robert C. Young
Robert C. Young
POWER OF ATTORNEY
The undersigned hereby authorizes and appoints Donald E. Morel, Jr. and John R. Gailey III, and each of them, as his attorneys-in-fact to sign on his behalf and in his capacity as a director of West Pharmaceutical Services, Inc., and to file, the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2011 and all amendments, exhibits and supplements thereto.
Date: February 21, 2012 /s/ Patrick J. Zenner
Patrick J. Zenner